跳至主要内容
临床试验/NCT01798420
NCT01798420已完成不适用

The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

The Nazareth Hospital, Israel1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2012年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
42
试验地点
1
主要终点
Hemoglobin A1C LEVEL

研究概览

简要总结

Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to significantly increase hemoglobin A1C levels

详细描述

HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid dose were documented. Age- and sex-matched group of diabetic patients with COPD who were admitted for other reasons, were asked to participate as a control group. Mann-Whitney and Chi square/Fischer's exact tests were used to compare between the parameters of the two groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3 months later. Multi-variate linear regression analysis was used to find predictors for increase in HbA1C levels in the patients' group.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetic patients with COPD exacerbation

排除标准

  • Patients treated with steroids during the previous 3 months

结局指标

主要结局

Hemoglobin A1C LEVEL

时间窗: 3 MONTHS

次要结局

  • Glucose levels(3 months)

研究者

发起方
The Nazareth Hospital, Israel
申办方类型
Other
责任方
Principal Investigator
主要研究者

George Habib

Head, Rheumatology clinic, Nzareth hospital, Nzareth

The Nazareth Hospital, Israel

研究点 (1)

Loading locations...

相似试验